Brand loyalty, generic entry and price competition in pharmaceuticals in the quarter century after the 1984 Waxman-Hatch legislation

International Journal of the Economics of Business

Volumn 18, Issue 2, 2011, Pages 177-201

  Berndt, Ernst R ^a   Aitken, Murray L ^b  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b IMS Institute for Healthcare Informatics   (United States)

Author keywords

Brand drugs; Branded generic drugs; Generic drugs; Pharmaceuticals; Price competition; Waxman hatch legislation

Indexed keywords

EID: 79961134266     PISSN: 13571516     EISSN: 14661829     Source Type: Journal    
DOI: 10.1080/13571516.2011.584423     Document Type: Article

References (23)

1. Aitken, Murray, Berndt, Ernst R., and Cutler, David M. (2008) Prescription drug spending trends in the United States: looking beyond the turning point, Health Affairs Web Exclusive, 28:w151-w160, 2009; published online 16 December 2008, DOI: 10.1377/hlthaff.28.1.w151.
2. Berndt, Ernst R. (2001) The US pharmaceutical industry: why major growth in times of cost containment? Health Affairs, 20, pp. 100-114, March/April.
3. Berndt, Ernst R., Cutler, David M., Frank, Richard G., Zvi, Griliches, Newhouse, Joseph P., and Triplett, Jack E. (2000) Medical care prices and output, in: Anthony Culyer and Joseph P. Newhouse (Eds), Handbook of Health Economics (Amsterdam New York: Elsevier Sciences B.V), vol. 1A, pp. 117-80 (chapter 3).
4. Berndt, Ernst R., Mortimer, Richard, Bhattacharjya, Ashoke, Parece, Andrew, and Tuttle, Edward (2007) Authorized generic drugs, price competition and consumers' welfare, Health Affairs, 26, pp. 790-799, May/June.
5. Berndt, Ernst R., and Newhouse, Joseph P. (2010) Pricing and Reimbursement in US Pharmaceutical Markets (Cambridge, MA: National Bureau of Economic Research), Working Paper No. 16297, August.
6. Cook, Anna (1998) How Increased Competition from Generic Drugs Has Affected Prices and Returns in the Pharmaceutical Industry (Washington, DC: The Congress of the United States, Congressional Budget Office). Available at: http://www.cbo.gov/.
7. Crawford, Pamela, Feely, Morgan, Guberman, Alan, and Kramer, Gunter (2006) Are there potential problems with generic substitution of antiepileptic drugs? A review of issues, Seizure, 15, pp. 165-176, April.
8. Dinan, Stephen (2010) Bush drug plan beats cost mark: could be omen for health law, Washington Times, 10 August. Available at: http://www.washingtontimes.com/news/2010/aug/16/bushdrug-plan-beats-cost-mark/print (last accessed 17 August 2010).
9. Federal Trade Commission (2009) Authorized Generics: An Interim Report of the Federal Trade Commission, 24 June. Available at: http://www.ftc.gov.
10. Generic Pharmaceutical Association (2010) Savings Achieved Through the Use of Generic Pharmaceuticals 2000-2009 (Washington, DC: Generic Pharmaceutical Association), July. Available at: www.gphaonline.org.
11. Grabowski, Henry G., and Vernon, John M. (1992) Brand loyalty, entry, and price competition in pharmaceuticals after the 1984 Drug Act, Journal of Law and Economics, 35, pp. 331-340, October.
12. Grabowski, Henry G., and Vernon, John M. (1996) Longer patents for increased generic competition in the US: The Waxman-Hatch Act after one decade, Pharmacoeconomics, 10 Suppl 2, pp. 110-23.
13. Gross, David J., Schondelmeyer, Stephen W., and Purvis, Leigh (2008) Rx Watchdog Report: Trends in Manufacturer Prices of Brand Name Prescription Drugs Used by Medicare Beneficiaries, 2002 to 2007, AARP Public Policy Institute #2008-05, March. Available at: http://www.aarp.org/ppi.
14. LeLorier, Jacques., Duh, Mei S., Paradis, Pierre E., Lefebvre, Patrick, Weiner, Jennifer, Manjunath, Ranjani, and Sheehy, Odile (2008) Clinical consequences of generic substitution of lamotrigine for patients with epilepsy, Neurology, 70, pp. 2179-86.
15. Purvis, Leigh, and Schondelmeyer, Stephen W. (2010) Rx Watchdog Report: Brand Name Drug Prices Continue to Climb Despite Low General Inflation Rate, Insight on the Issues 43, AARP Public Policy Institute, May. Available at: http://www.aarp.org/ppi.
16. Scherer F. Michael, and Ross, David (1990) Market structure, patents and technological innovation, in: F. Michael Scherer and David Ross (Eds), Industrial Structure and Economic Performance, 3rd ed., (Boston: Houghton Mifflin Company), chapter 17.
17. Schondelmeyer, Stephen W., and Purvis, Leigh (2010) Rx price watch report: trends in retail prices of brand name prescription drugs used by medicare beneficiaries, 2005 to 2009, AARP Public Policy Issues, Report #2010-06, August. Available at: http://www.aarp.org/ppi.
18. Schondelmeyer, Stephen W., Purvis, Leigh, and Gross, David J. (2009a) Rx Watchdog Report: Comparative Measures of Price Change for Prescription Drugs and Other Goods, AARP Public Policy Institute, Report #2009-16, November. Available at: http://www.aarp.org/ppi.
19. Schondelmeyer, Stephen W., Purvis, Leigh, and Gross, David J. (2009b) Rx Watchdog Report: Drug Prices Continue to Climb Despite Lack of Growth in General Inflation Rate, Insight on the Issues, AARP Public Policy Issues, November. Available at: http://www.aarp.org/ppi.
20. Schondelmeyer, Stephen W., and Wrobel, Marian V. (2004) Medicaid and Medicare Drug Pricing: Strategy to Determine Market Prices, Cambridge, MA: Abt Associates Inc., Introduction Final Report, Contract #500-00-0049, Task Order 1, 30 August. Available at: http://www.abtassociates.com/reports/20040830_500_00_0049.pdf.
21. Smith, Aaron (2007) Federal judge whacks generic Plavix, CNN Money.com, 19 June. Available at: http://money.cnn.com/2007/06/19/news/companies/plavix/index.htm.
22. Suh, Dong-Churl, Schondelmeyer, Stephen W., Manning, Willard G. Jr., Hadsall, Ronald S., and Nyman, John A. (1998) Price trends before and after patent expiration in the pharmaceutical industry, Journal of Research in Pharmaceutical Economics, 9, pp. 17-31.
23. Trusheim, Mark R., Aitken, Murray L., and Berndt, Ernst R. (2010) Characterizing markets for biopharmaceutical innovations: do biologics differ from small molecules? Forum for Health Economics & Policy, 13, (Frontiers in Health Policy Research) Article 4. Available at: http://www.bepress.com/fhep/13/1/4.